Bi, Youwei

FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC

Nakajima, E. C., Drezner, N., Li, X., Mishra-Kalyani, P. S., Liu, Y., Zhao, H., Bi, Y., Liu, J., Rahman, A., Wearne, E., et al. (2022) · Clinical Cancer Research

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 333

FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements

Gandhy, S. U., Casak, S. J., Mushti, S. L., Cheng, J., Subramaniam, S., Zhao, H., Zhao, M., Bi, Y., Liu, G., Fan, J., et al. (2023) · Clinical Cancer Research

Cholangiocarcinoma and Gallbladder Cancer StudiesPediatric Hepatobiliary Diseases and Treatments

Cited by 25